

2016-2017 Influenza Season Week 48 ending December 3, 2016

All data are preliminary and may change as more reports are received.

Synopsis: During week 48 (November 27-December 3, 2016), influenza activity increased slightly, but remained low in the United States.

- **Viral Surveillance:** The most frequently identified influenza virus subtype reported by public health laboratories during week 48 was influenza A (H3). The percentage of respiratory specimens testing positive for influenza in clinical laboratories remained low.
- **Pneumonia and Influenza Mortality:** Due to data processing problems, the National Center for Health Statistics (NCHS) mortality surveillance data for the week ending November 19, 2016 (week 46) will not be published this week.
- **Influenza-associated Pediatric Deaths:** No influenza-associated pediatric deaths were reported.
- **Outpatient Illness Surveillance:** The proportion of outpatient visits for influenza-like illness (ILI) was 1.8%, which is below the national baseline of 2.2%. Two regions reported ILI at or above their region-specific baseline levels. Puerto Rico experienced high ILI activity, New York City and four states experienced low ILI activity, 46 states experienced minimal ILI activity, and the District of Columbia had insufficient data.
- **Geographic Spread of Influenza:** The geographic spread of influenza in Puerto Rico was reported as widespread; Guam and two states were reported as regional; 19 states reported local activity; the U.S. Virgin Islands and 28 states reported sporadic activity; one state reported no activity; and the District of Columbia did not report.

National and Regional Summary of Select Surveillance Components

HHS Surveillance Regions*	Data for current week			Data cumulative since October 2, 2016 (week 40)						
	Out-patient ILI†	Number of jurisdictions reporting regional or widespread activity	% respiratory specimens positive for flu in clinical laboratories‡	A(H1N1) pdm09	A (H3)	A (Subtyping not performed)	B Victoria lineage	B Yamagata lineage	B lineage not performed	Pediatric Deaths
Nation	Normal	4 of 54	3.5%	73	899	78	37	23	50	0
Region 1	Normal	0 of 6	1.9%	0	41	0	0	0	0	0
Region 2	Elevated	1 of 4	2.0%	0	70	2	16	4	3	0
Region 3	Normal	0 of 6	0.9%	7	66	9	1	2	7	0
Region 4	Elevated	2 of 8	6.1%	5	76	10	3	2	29	0
Region 5	Normal	0 of 6	1.4%	3	68	41	7	4	2	0
Region 6	Normal	0 of 5	2.0%	11	24	0	5	5	0	0
Region 7	Normal	0 of 4	1.6%	0	22	1	2	0	0	0
Region 8	Normal	0 of 6	2.7%	28	89	2	0	0	0	0
Region 9	Normal	1 of 5	3.0%	18	241	11	1	6	5	0
Region 10	Normal	0 of 4	8.7%	1	202	2	2	0	4	0

*<http://www.hhs.gov/about/agencies/staff-divisions/iea/regional-offices/index.html>

† Elevated means the % of visits for ILI is at or above the national or region-specific baseline.

§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands

‡ National data are for current week; regional data are for the most recent three weeks.


U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories, which include both public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of Columbia, report to CDC the total number of respiratory specimens tested for influenza and the number positive for influenza by virus type. In addition, public health laboratories also report the influenza A subtype (H1 or H3) and influenza B lineage information for the viruses they test and the age or age group of the persons from whom the specimens were collected.

Additional virologic data can be found at: <http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html> and http://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html.

The results of tests performed by clinical laboratories are summarized below.

	Week 48	Data Cumulative since October 2, 2016 (week 40)
No. of specimens tested	15,262	135,871
No. of positive specimens (%)	535 (3.5%)	3,087 (2.3%)
Positive specimens by type		
Influenza A	390 (72.9%)	2,052 (66.5%)
Influenza B	145 (27.1%)	1,035 (33.5%)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2016-2017 Season




The results of tests performed by public health laboratories, as well as the age group distribution of influenza positive tests, are summarized below.


	Week 48	Data Cumulative since October 2, 2016 (week 40)
No. of specimens tested	783	9,049
No. of positive specimens*	154	1,160
<i>Positive specimens by type/subtype</i>		
Influenza A	141 (91.6%)	1,050 (90.5%)
A(H1N1)pmd09	6 (4.3%)	73 (7.0%)
H3	112 (79.4%)	899 (85.6%)
Subtyping not performed	23 (16.3%)	78 (7.4%)
Influenza B	13 (8.4%)	110 (9.5%)
Yamagata lineage	2 (15.4%)	23 (20.9%)
Victoria lineage	2 (15.4%)	37 (33.6%)
Lineage not performed	9 (69.2%)	50 (45.5%)

*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity. Additional information is available at <http://www.cdc.gov/flu/weekly/overview.htm>

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2016-2017 Season



Age Group Proportions and Total by Influenza Subtype Reported by Public Health Laboratories, 2016-2017 Season



Influenza Virus Characterization: CDC characterizes influenza viruses through one or more tests including [genomic sequencing](#), [hemagglutination inhibition \(HI\)](#) and/or neutralization assays. These data are used to compare how similar currently circulating influenza viruses are to the reference viruses used for developing influenza vaccines, and to monitor for changes in circulating influenza viruses. Historically, HI data have been used most commonly to assess the similarity between reference viruses and circulating viruses to suggest how well the vaccine may work until such a time as [vaccine effectiveness estimates](#) are available.

For nearly all virus positive surveillance samples received at CDC, next-generation sequencing is performed to ascertain genomic data of circulating influenza viruses. Viruses can be classified into genetic groups/clades based on analysis of their HA gene segments using phylogenetics and key amino acid changes ([Klimov Vaccine 2012](#)).

A proportion of influenza A (H3N2) viruses don't yield sufficient hemagglutination titers for antigenic characterization using the hemagglutination inhibition test. Therefore, CDC selects a subset of influenza A (H3N2) viruses to test using a focus reduction assay for supplementary antigenic characterization.


Genetic Characterization

During the 2016-2017 season, 1,160 influenza positive specimens have been collected and reported by public health laboratories in the United States (figure, left). CDC genetically characterized 141 influenza viruses [17 influenza A (H1N1)pdm09, 101 influenza A (H3N2), and 23 influenza B viruses] collected by U.S. laboratories. The HA gene segment of all influenza A (H1N1)pdm09 viruses analyzed belonged to genetic group 6B.1. Influenza A (H3N2) virus HA gene segments analyzed belonged to genetic groups 3C.2a or 3C.3a. Genetic group 3C.2a includes a newly emerging subgroup known as 3C.2a1. The HA of influenza B/Victoria-lineage viruses all belonged to genetic group V1A. The HA of influenza B/Yamagata-lineage viruses analyzed all belonged to genetic group Y3.


The majority of U.S. viruses submitted for characterization come from state and local public health laboratories. Due to [Right Size Roadmap](#) considerations, specimen submission guidance issued to the laboratories request that, if available, 2 influenza A (H1N1), 2 A influenza (H3N2), and 2 influenza B viruses be submitted every other week. Because of this, the number of each virus type/subtype characterized should be approximately equal. In the figure below, the results of tests performed by public health labs are presented on the left and sequence results by genetic group of specimens submitted to CDC are presented on the right.

Sequence Results, by Genetic Group, of Specimens Submitted to CDC by U.S. Public Health Laboratories, Cumulative, 2016-2017 season

Influenza Positive Specimens Reported by U.S. Public Health Laboratories, Cumulative, 2016-2017 season



- Influenza A (H3)
- Influenza A (H1pdm09)
- Influenza A (subtype unknown)
- Influenza B Victoria
- Influenza B Yamagata
- Influenza B (lineage not determined)



Antigenic Characterization: CDC has antigenically characterized 38 influenza viruses [8 influenza A (H1N1)pdm09, 16 influenza A (H3N2), and 14 influenza B viruses] collected by U.S. laboratories since October 1, 2016.

Influenza A Virus [24]

A (H1N1)pdm09 [8]: All 8 (100%) influenza A (H1N1)pdm09 viruses were antigenically characterized using ferret post-infection antisera as A/California/7/2009-like, the influenza A (H1N1) component of the 2016-2017 Northern Hemisphere vaccine.

A (H3N2) [16]: All 16 (100%) influenza A (H3N2) viruses were antigenically characterized as A/Hong Kong/4801/2014-like, a virus that belongs in genetic group 3C.2a and is the influenza A (H3N2) component of the 2016-2017 Northern Hemisphere vaccine, by HI testing or neutralization testing.

Influenza B Virus [14]

Victoria Lineage [6]: 5 of 6 (83%) B/Victoria-lineage viruses were antigenically characterized using ferret post-infection antisera as B/Brisbane/60/2008-like, which is included as an influenza B component of the 2016-2017 Northern Hemisphere trivalent and quadrivalent influenza vaccines.

Yamagata Lineage [8]: All 8 (100%) B/Yamagata-lineage viruses were antigenically characterized using ferret post-infection antisera as B/Phuket/3073/2013-like, which is included as an influenza B component of the 2016-2017 Northern Hemisphere quadrivalent influenza vaccines.

Antiviral Resistance: Testing of influenza A (H1N1)pdm09, influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is performed at CDC using a functional assay. Additional influenza A (H1N1)pdm09 and influenza A (H3N2) clinical samples are tested for mutations of the virus known to confer oseltamivir resistance. The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A (H1N1)pdm09 and influenza A (H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, data from adamantane resistance testing are not presented below.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2016

	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)
Influenza A (H1N1)pmd09	24	0 (0.0)	24	0 (0.0)	24	0 (0.0)
Influenza A (H3N2)	104	0 (0.0)	104	0 (0.0)	80	0 (0.0)
Influenza B	28	0 (0.0)	28	0 (0.0)	28	0 (0.0)

The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of oseltamivir-resistant and peramivir-resistant influenza A (H1N1)pdm09 viruses and oseltamivir-resistant influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment as early as possible is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at [high risk](#) for serious influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at <http://www.cdc.gov/flu/antivirals/index.htm>.


[Pneumonia and Influenza \(P&I\) Mortality Surveillance](#): Due to data processing problems, the National Center for Health Statistics (NCHS) mortality surveillance data for the week ending November 19, 2016 (week 46) will not be published this week. Instead, updated data thru the week ending November 12, 2016 (week 45) is presented below.

Background: Weekly mortality surveillance data includes a combination of machine coded and manually coded causes of death collected from death certificates. There is a backlog of data requiring manual coding within NCHS mortality surveillance data. The percentages of deaths due to P&I are higher among manually coded records than more rapidly available machine coded records and may result in initially reported P&I percentages that are lower than percentages calculated from final data. Efforts continue to reduce and monitor the number of records awaiting manual coding.

Beginning in the week ending October 8, 2016 (week 40), CDC retired the 122 Cities Mortality Reporting System and uses only the NCHS Mortality Surveillance System.

Region and state-specific data are available at <http://gis.cdc.gov/grasp/fluview/mortality.html>.


Pneumonia and Influenza Mortality from
the National Center for Health Statistics Mortality Surveillance System
Data through the week ending November 12, 2016, as of December 8, 2016



Influenza-Associated Pediatric Mortality: No influenza-associated pediatric deaths were reported to CDC during week 48.

Additional data can be found at: <http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html>.

Number of Influenza-Associated Pediatric Deaths by Week of Death:
2013-2014 season to present




Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in the Emerging Infections Program (EIP) states and Influenza Hospitalization Surveillance Project (IHSP) states. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season. Additional FluSurv-NET data can be found at: <http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html> and <http://gis.cdc.gov/grasp/fluview/FluHospChars.html>.











Outpatient Illness Surveillance: Nationwide during week 48, 1.8% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.2%. (ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.)

Additional data are available at <http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>.

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2016-2017 and Selected Previous Seasons



On a regional level, the percentage of outpatient visits for ILI ranged from 0.8% to 3.5% during week 48. Two regions (regions 2 and 4) reported a proportion of outpatient visits for ILI at or above their region-specific baseline levels.



NOTE: Scales differ between regions. Regional baselines are calculated each influenza season and may differ from season to season.
 *Use of the regional baselines for state data is not appropriate.

— % ILI - - - - - Baseline*




ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI and are compared to the average percent of ILI visits that occur during weeks with little or no influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity from outpatient clinics being below, or only slightly above, the average, to high, which would correspond to ILI activity from outpatient clinics being much higher than average.

During week 48, the following ILI activity levels were experienced:

- Puerto Rico experienced high ILI activity.
- New York City and four states (Colorado, Georgia, Louisiana, and Nevada) experienced low ILI activity.
- 46 states (Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming) experienced minimal ILI activity.
- Data were insufficient to calculate an ILI activity level from the District of Columbia.

**Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINet
2016-17 Influenza Season Week 48 ending Dec 03, 2016**



*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.

Data collected in ILINet may disproportionately represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state.


Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data are received.

Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses, but does not measure the severity of influenza activity.

During week 48, the following influenza activity was reported:

- Widespread influenza activity was reported by Puerto Rico.
- Regional influenza activity was reported by Guam and two states (Alabama and North Carolina).
- Local influenza activity was reported by 19 states (Arizona, Connecticut, Delaware, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Hampshire, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Virginia, and Washington).
- Sporadic influenza activity was reported by the U.S. Virgin Islands and 28 states (Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Michigan, Mississippi, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York, North Dakota, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wisconsin, and Wyoming).
- No activity was reported by one state (Rhode Island).
- The District of Columbia did not report.



* This map indicates geographic spread & does not measure the severity of influenza activity

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit <http://www.cdc.gov/flu/weekly/fluviewinteractive.htm>.

U.S. State, territorial, and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information.

Alabama	Alaska	Arizona	Arkansas	California
Colorado	Connecticut	Delaware	District of Columbia	Florida
Georgia	Hawaii	Idaho	Illinois	Indiana
Iowa	Kansas	Kentucky	Louisiana	Maine
Maryland	Massachusetts	Michigan	Minnesota	Mississippi
Missouri	Montana	Nebraska	Nevada	New Hampshire
New Jersey	New Mexico	New York	North Carolina	North Dakota
Ohio	Oklahoma	Oregon	Pennsylvania	Rhode Island
South Carolina	South Dakota	Tennessee	Texas	Utah
Vermont	Virginia	Washington	West Virginia	Wisconsin
Wyoming	New York City	Puerto Rico	U.S. Virgin Islands	

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through [FluNet](#) and the [Global Epidemiology Reports](#).

WHO Collaborating Centers for Influenza located in [Australia](#), [China](#), [Japan](#), the [United Kingdom](#), and the [United States](#) (CDC in Atlanta, Georgia).

Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European Centre for Disease Prevention and Control at <http://www.flunewseurope.org/>

Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at <http://www.phac-aspc.gc.ca/fluwatch/>.

Public Health England: The most up-to-date influenza information from the United Kingdom is available at <https://www.gov.uk/government/statistics/weekly-national-flu-reports>.

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at: <http://www.cdc.gov/flu/weekly/overview.htm>.

Report prepared: December 9, 2016.

**WHO Collaborating Laboratory Reports
2016-2017 Influenza Season**

National

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	82	898	0	9	86	0	2	5	3	260	13313	225	1.69	128	97
201641	83	956	0	8	80	0	4	6	5	255	13713	187	1.36	104	83
201642	85	1108	3	11	121	0	1	6	8	254	14366	209	1.45	114	95
201643	83	1124	6	13	110	0	6	3	2	231	14326	221	1.54	138	83
201644	84	1179	9	10	87	0	4	9	1	229	15450	302	1.95	188	114
201645	76	1058	3	5	92	0	6	4	0	224	16304	379	2.32	258	121
201646	80	1124	12	8	129	0	10	1	1	223	17173	466	2.71	325	141
201647	74	819	22	3	82	0	8	1	1	212	15964	563	3.53	407	156
201648	67	783	23	6	112	0	9	2	2	174	15262	535	3.51	390	145
Total	0	9049	78	73	899	0	50	37	23	.	135871	3087	2.27	2052	1035

Region 1 (CT, ME, MA, NH, RI, VT)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	6	31	0	0	6	0	0	0	0	20	623	6	0.96	6	0
201641	5	14	0	0	2	0	0	0	0	20	754	5	0.66	5	0
201642	6	25	0	0	3	0	0	0	0	20	807	2	0.25	1	1
201643	6	30	0	0	5	0	0	0	0	20	740	2	0.27	2	0
201644	6	33	0	0	8	0	0	0	0	20	702	6	0.85	5	1
201645	5	23	0	0	1	0	0	0	0	20	779	4	0.51	3	1
201646	6	37	0	0	8	0	0	0	0	20	831	11	1.32	10	1
201647	5	17	0	0	1	0	0	0	0	19	777	11	1.42	8	3
201648	5	18	0	0	7	0	0	0	0	18	947	26	2.75	26	0
Total	0	228	0	0	41	0	0	0	0	.	6960	73	1.05	66	7

Region 2 (NJ, NY, PR)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	5	31	0	0	6	0	0	2	0	17	1296	12	0.93	9	3
201641	6	50	0	0	7	0	1	5	2	16	1290	5	0.39	2	3
201642	6	62	0	0	17	0	1	1	2	15	1405	17	1.21	16	1
201643	6	59	0	0	23	0	0	1	0	15	1392	8	0.57	5	3
201644	5	66	0	0	9	0	0	5	0	15	1422	11	0.77	10	1
201645	5	40	0	0	2	0	0	0	0	15	1473	13	0.88	12	1
201646	4	33	0	0	3	0	1	0	0	15	1497	18	1.20	17	1
201647	5	33	2	0	2	0	0	0	0	13	1355	25	1.85	23	2
201648	4	24	0	0	1	0	0	2	0	13	1654	47	2.84	39	8
Total	0	398	2	0	70	0	3	16	4	.	12784	156	1.22	133	23

Region 3 (DE, DC, MD, PA, VA, WV)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	6	114	0	2	2	0	0	0	0	25	937	5	0.53	1	4
201641	7	126	0	0	1	0	0	0	0	24	957	4	0.42	3	1
201642	6	157	0	0	2	0	0	0	0	23	1005	1	0.10	0	1
201643	6	175	0	1	8	0	0	0	0	22	1036	3	0.29	1	2
201644	6	192	0	1	5	0	0	0	1	21	1058	1	0.09	0	1
201645	6	189	0	1	8	0	1	1	0	20	972	4	0.41	1	3
201646	6	178	1	1	10	0	1	0	0	18	1002	5	0.50	3	2
201647	5	145	3	1	9	0	3	0	0	18	910	9	0.99	5	4
201648	6	140	5	0	21	0	2	0	1	16	771	11	1.43	7	4
Total	0	1416	9	7	66	0	7	1	2	.	8648	43	0.50	21	22

Region 4 (AL, FL, GA, KY, MS, NC, SC, TN)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	9	112	0	1	11	0	1	2	0	45	3044	115	3.78	50	65
201641	11	132	0	0	10	0	1	0	1	44	2723	93	3.42	47	46
201642	10	155	2	1	7	0	0	0	1	44	2948	101	3.43	41	60
201643	10	152	0	0	8	0	5	0	0	43	2943	91	3.09	40	51
201644	13	183	0	0	6	0	3	1	0	43	3457	164	4.74	78	86
201645	10	223	0	1	5	0	4	0	0	44	3537	183	5.17	97	86
201646	10	214	0	1	10	0	6	0	0	43	3954	196	4.96	107	89
201647	10	163	2	0	6	0	5	0	0	42	3920	257	6.56	142	115
201648	6	97	6	1	13	0	4	0	0	31	3530	238	6.74	134	104
Total	0	1431	10	5	76	0	29	3	2	.	30056	1438	4.78	736	702

Region 5 (IL, IN, MI, MN, OH, WI)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	9	204	0	0	7	0	0	0	1	60	2381	14	0.59	8	6
201641	11	202	0	0	7	0	0	0	0	60	2703	15	0.55	8	7
201642	11	216	1	0	14	0	0	2	1	61	2893	28	0.97	14	14
201643	11	230	2	1	6	0	0	1	0	41	2705	11	0.41	7	4
201644	11	248	4	1	7	0	0	1	0	42	2973	26	0.87	17	9
201645	12	228	2	0	6	0	0	1	0	40	3139	17	0.54	11	6
201646	13	244	11	0	14	0	0	1	1	41	3200	37	1.16	23	14
201647	7	168	9	0	2	0	0	1	0	40	2987	48	1.61	39	9
201648	7	188	12	1	5	0	2	0	1	30	2869	39	1.36	28	11
Total	0	1928	41	3	68	0	2	7	4	.	25850	235	0.91	155	80

Region 6 (AR, LA, NM, OK, TX)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	7	42	0	1	0	0	0	0	0	31	1761	43	2.44	25	18
201641	7	38	0	0	0	0	0	0	0	30	1851	36	1.94	15	21
201642	9	75	0	1	4	0	0	2	3	30	1876	23	1.23	10	13
201643	8	80	0	1	3	0	0	0	2	29	1881	36	1.91	18	18
201644	7	86	0	2	2	0	0	1	0	29	2037	31	1.52	19	12
201645	6	64	0	1	1	0	0	2	0	29	2371	41	1.73	20	21
201646	7	98	0	3	4	0	0	0	0	29	2744	67	2.44	40	27
201647	7	55	0	0	6	0	0	0	0	26	2280	45	1.97	31	14
201648	6	65	0	2	4	0	0	0	0	20	1825	27	1.48	19	8
Total	0	603	0	11	24	0	0	5	5	.	18626	349	1.87	197	152

Region 7 (IA, KS, MO, NE)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	5	24	0	0	2	0	0	1	0	16	728	0	0.00	0	0
201641	4	23	0	0	1	0	0	0	0	15	786	1	0.13	1	0
201642	7	27	0	0	1	0	0	0	0	15	822	2	0.24	0	2
201643	5	26	0	0	2	0	0	0	0	15	882	2	0.23	1	1
201644	5	26	1	0	1	0	0	1	0	15	845	2	0.24	0	2
201645	5	18	0	0	0	0	0	0	0	16	874	1	0.11	1	0
201646	4	24	0	0	4	0	0	0	0	15	958	9	0.94	6	3
201647	4	22	0	0	5	0	0	0	0	16	874	15	1.72	13	2
201648	5	36	0	0	6	0	0	0	0	12	926	21	2.27	19	2
Total	0	226	1	0	22	0	0	2	0	.	7695	53	0.69	41	12

Region 8 (CO, MT, ND, SD, UT, WY)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	7	46	0	2	8	0	0	0	0	14	870	8	0.92	8	0
201641	7	51	0	6	6	0	0	0	0	14	929	10	1.08	9	1
201642	8	60	0	3	7	0	0	0	0	13	907	7	0.77	7	0
201643	8	65	0	9	14	0	0	0	0	13	974	9	0.92	9	0
201644	8	68	1	3	11	0	0	0	0	13	955	14	1.47	14	0
201645	6	39	0	1	12	0	0	0	0	13	1085	23	2.12	23	0
201646	6	51	0	3	11	0	0	0	0	13	1059	18	1.70	17	1
201647	6	32	1	1	16	0	0	0	0	12	998	28	2.81	27	1
201648	4	19	0	0	4	0	0	0	0	12	1174	42	3.58	42	0
Total	0	431	2	28	89	0	0	0	0	.	8951	159	1.78	156	3

Region 9 (AZ, CA, GU, HI, NV)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	33	177	0	3	27	0	1	0	2	22	1066	8	0.75	7	1
201641	35	184	0	2	26	0	1	1	2	20	1097	12	1.09	10	2
201642	33	201	0	6	41	0	0	0	1	22	1089	9	0.83	7	2
201643	33	195	4	0	20	0	0	0	0	21	1044	16	1.53	14	2
201644	33	202	2	3	14	0	1	0	0	19	1135	17	1.50	16	1
201645	34	175	0	1	26	0	1	0	0	19	1210	20	1.65	18	2
201646	31	178	0	0	31	0	0	0	0	18	915	16	1.75	14	2
201647	31	151	5	1	21	0	0	0	1	18	800	26	3.25	21	5
201648	28	167	0	2	35	0	1	0	0	13	956	39	4.08	32	7
Total	0	1630	11	18	241	0	5	1	6	.	9312	163	1.75	139	24

Region 10 (AK, ID, OR, WA)

CDC Week	Public Health Labs	Public Health Specimens Tested	AUNK	AH1N1 pdm09	AH3N2	AH3N2v	B	BVic	BYam	Clinical Labs	Clinical Specimens Tested	Clinical Flu Positive	% Positive	A	B
201640	6	117	0	0	17	0	0	0	0	12	607	14	2.31	14	0
201641	5	136	0	0	20	0	1	0	0	12	623	6	0.96	4	2
201642	6	130	0	0	25	0	0	1	0	11	614	19	3.09	18	1
201643	5	112	0	1	21	0	1	1	0	12	729	43	5.90	41	2
201644	6	75	1	0	24	0	0	0	0	12	866	30	3.46	29	1
201645	5	59	1	0	31	0	0	0	0	11	864	73	8.45	72	1
201646	6	67	0	0	34	0	2	0	0	11	1013	89	8.79	88	1
201647	5	33	0	0	14	0	0	0	0	11	1063	99	9.31	98	1
201648	4	29	0	0	16	0	0	0	0	9	610	45	7.38	44	1
Total	0	758	2	1	202	0	4	2	0	.	6989	418	5.98	408	10

NCHS Mortality Surveillance Data
Data as of December 8, 2016
For the Week Ending November 12, 2016 (Week 45)

YEAR	WEEK	% OF DEATHS	EXPECTED	THRESH.	TOTAL DEATHS	PNEUMONIA DEATHS	INFLUENZA DEATHS
2016	38	5.68	5.77	6.05	40649	2302	6
2016	39	5.43	5.83	6.11	40421	2190	6
2016	40	5.47	5.90	6.18	40295	2192	13
2016	41	5.69	5.98	6.26	39096	2214	10
2016	42	5.64	6.06	6.34	36918	2074	7
2016	43	5.59	6.15	6.43	35815	1990	11
2016	44	5.60	6.25	6.53	33738	1881	9
2016	45	5.35	6.34	6.62	30821	1640	10

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
National (Baseline: 2.2%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	1898	3085	4074	2108	803	587	10657	839633	1.3	1.2
201641	1914	3180	3984	2116	848	635	10763	817524	1.3	1.3
201642	1913	3533	4359	2211	952	668	11723	847503	1.4	1.3
201643	1925	3736	4616	2369	957	674	12352	837199	1.5	1.4
201644	1896	4242	5079	2415	1007	686	13429	833629	1.6	1.5
201645	1853	4578	4948	2451	994	710	13681	808615	1.7	1.6
201646	1834	4813	5295	2579	1016	780	14483	821196	1.8	1.7
201647	1801	4835	4366	2478	1037	766	13482	640768	2.1	1.9
201648	1644	4796	4910	3011	1236	858	14811	737718	2.0	1.8
<i>Totals</i>							<i>115381</i>	<i>7183785</i>		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 1 (CT, ME, MA, NH, RI, and VT) (Baseline: 1.4%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	133	68	174	52	24	16	334	49596	0.7	0.8
201641	133	70	138	33	18	17	276	46805	0.6	0.7
201642	128	98	171	42	20	18	349	49727	0.7	0.8
201643	131	90	166	38	23	12	329	50254	0.7	0.7
201644	128	119	193	50	21	15	398	49115	0.8	1.0
201645	130	111	193	35	18	10	367	50460	0.7	0.9
201646	124	115	168	44	15	15	357	48480	0.7	1.0
201647	121	96	79	23	17	12	227	30319	0.7	0.9
201648	101	101	106	39	18	10	274	42134	0.7	0.8
<i>Totals</i>							<i>2911</i>	<i>416890</i>		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 2 (NJ, NY, PR, and USVI) (Baseline: 3.0%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	172	805	693	420	170	106	2194	131851	1.7	1.9
201641	167	825	680	427	190	106	2228	129152	1.7	2.1
201642	173	910	740	450	185	130	2415	135277	1.8	2.1
201643	178	970	746	410	175	128	2429	130830	1.9	2.2
201644	169	1081	857	433	210	133	2714	132229	2.1	2.3
201645	164	1254	864	434	224	133	2909	128360	2.3	2.7
201646	167	1347	963	445	196	149	3100	134607	2.3	2.7
201647	169	1387	976	456	202	160	3181	110923	2.9	3.5
201648	150	1573	1081	525	230	156	3565	128193	2.8	3.5
<i>Totals</i>							24735	1161422		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 3 (DE, DC, MD, PA, VA, and WV) (Baseline: 2.2%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	292	416	743	443	177	109	1888	133121	1.4	1.1
201641	296	417	736	511	158	137	1959	134673	1.5	1.1
201642	297	504	764	517	161	95	2041	141397	1.4	1.2
201643	294	551	819	538	187	92	2187	135265	1.6	1.3
201644	296	630	881	555	203	101	2370	136501	1.7	1.4
201645	290	673	785	553	184	113	2308	132810	1.7	1.5
201646	285	735	809	581	197	126	2448	135927	1.8	1.5
201647	279	767	782	571	175	141	2436	114828	2.1	1.8
201648	258	719	773	683	218	150	2543	126676	2.0	1.7
<i>Totals</i>							20180	1191198		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 4 (AL, FL, GA, KY, MS, NC, SC, and TN) (Baseline: 1.7%)
Data as of Friday, December 9, 2016**

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
201640	305	644	797	379	117	85	2022	160060	1.3	1.2
201641	310	714	762	398	153	96	2123	143872	1.5	1.3
201642	315	782	874	413	185	93	2347	151138	1.6	1.3
201643	313	771	974	526	197	107	2575	150043	1.7	1.4
201644	311	913	1129	514	198	121	2875	148802	1.9	1.7
201645	312	962	1106	547	185	139	2939	147493	2.0	1.7
201646	298	946	1177	589	222	141	3075	141156	2.2	2.0
201647	299	1039	919	536	245	137	2876	117849	2.4	2.1
201648	277	839	1051	738	268	225	3121	138708	2.3	1.9
<i>Totals</i>							23953	1299121		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 5 (IL, IN, MI, MN, OH, and WI) (Baseline: 1.9%)
Data as of Friday, December 9, 2016**

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
201640	284	312	445	162	81	72	1072	105474	1.0	1.0
201641	282	340	409	154	92	64	1059	104336	1.0	1.0
201642	277	368	560	153	98	72	1251	105786	1.2	1.0
201643	282	400	549	182	75	76	1282	103718	1.2	1.1
201644	275	469	599	218	105	71	1462	106261	1.4	1.3
201645	267	459	566	199	91	48	1363	97153	1.4	1.2
201646	268	486	558	237	95	60	1436	100802	1.4	1.2
201647	258	382	358	183	100	71	1094	72451	1.5	1.2
201648	226	364	428	207	82	64	1145	86078	1.3	1.2
<i>Totals</i>							11164	882059		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 6 (AR, LA, NM, OK, and TX) (Baseline: 4.1%)
Data as of Friday, December 9, 2016**

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
201640	241	493	582	313	120	95	1603	99428	1.6	1.8
201641	243	467	600	289	98	101	1555	93357	1.7	1.8
201642	240	458	527	290	108	104	1487	94041	1.6	1.7
201643	246	534	633	325	126	85	1703	96925	1.8	1.9
201644	238	594	654	303	117	96	1764	94755	1.9	2.0
201645	239	630	611	343	141	114	1839	89560	2.1	2.1
201646	239	694	702	324	148	125	1993	95187	2.1	2.3
201647	267	693	579	366	167	113	1918	80096	2.4	2.5
201648	264	808	785	522	290	154	2559	89457	2.9	2.5
Totals							16421	832806		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 7 (IA, KS, MO, and NE) (Baseline: 1.8%)
Data as of Friday, December 9, 2016**

CDC Week	# Sites Reporting	ILI 0-4 years	ILI 5-24 years	ILI 25-49 years	ILI 50-64 years	ILI 65 years and older	Total ILI	Total Patient Visits	% Unweighted ILI	% Weighted ILI
201640	68	26	49	29	15	19	138	20175	0.7	0.6
201641	71	27	57	40	18	12	154	19989	0.8	0.7
201642	73	31	72	52	27	11	193	20640	0.9	0.8
201643	74	27	51	52	16	14	160	21756	0.7	0.7
201644	72	28	79	51	20	15	193	20975	0.9	0.9
201645	73	45	92	51	9	10	207	21567	1.0	1.0
201646	67	41	96	45	18	11	211	20063	1.1	1.0
201647	64	51	71	47	19	17	205	12408	1.7	1.5
201648	59	54	107	53	23	23	260	17697	1.5	1.4
Totals							1721	175270		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 8 (CO, MT, ND, SD, UT, and WY) (Baseline: 1.4%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	111	70	159	98	15	16	358	40554	0.9	0.8
201641	116	70	156	78	26	17	347	43216	0.8	0.9
201642	114	100	136	76	29	11	352	40326	0.9	0.9
201643	120	107	156	76	18	18	375	45838	0.8	0.8
201644	120	78	132	71	19	9	309	43936	0.7	0.5
201645	120	101	173	92	23	26	415	44767	0.9	0.8
201646	115	103	187	93	21	14	418	44654	0.9	0.9
201647	112	113	155	75	15	20	378	36583	1.0	0.8
201648	108	118	224	100	28	26	496	42049	1.2	1.3
<i>Totals</i>							<i>3448</i>	<i>381923</i>		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 9 (AZ, CA, HI, and NV) (Baseline: 2.5%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	218	226	405	200	80	61	972	84167	1.2	1.3
201641	225	230	422	173	87	83	995	89502	1.1	1.3
201642	219	256	488	206	133	127	1210	95733	1.3	1.4
201643	211	261	488	210	136	138	1233	89169	1.4	1.5
201644	211	301	519	208	109	118	1255	87705	1.4	1.6
201645	192	303	503	192	108	110	1216	83351	1.5	1.6
201646	199	315	588	211	101	134	1349	87626	1.5	1.7
201647	161	286	413	208	90	87	1084	55693	1.9	2.0
201648	137	187	312	125	72	39	735	55209	1.3	1.2
<i>Totals</i>							<i>10049</i>	<i>728155</i>		

**U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
2016-2017 Influenza Season
HHS Region 10 (AK, ID, OR, and WA) (Baseline: 1.1%)
Data as of Friday, December 9, 2016**

<i>CDC Week</i>	<i># Sites Reporting</i>	<i>ILI 0-4 years</i>	<i>ILI 5-24 years</i>	<i>ILI 25-49 years</i>	<i>ILI 50-64 years</i>	<i>ILI 65 years and older</i>	<i>Total ILI</i>	<i>Total Patient Visits</i>	<i>% Unweighted ILI</i>	<i>% Weighted ILI</i>
201640	74	25	27	12	4	8	76	15207	0.5	0.5
201641	71	20	24	13	8	2	67	12622	0.5	0.5
201642	77	26	27	12	6	7	78	13438	0.6	0.5
201643	76	25	34	12	4	4	79	13401	0.6	0.5
201644	76	29	36	12	5	7	89	13350	0.7	0.6
201645	66	40	55	5	11	7	118	13094	0.9	0.8
201646	72	31	47	10	3	5	96	12694	0.8	0.7
201647	71	21	34	13	7	8	83	9618	0.9	0.8
201648	64	33	43	19	7	11	113	11517	1.0	0.9
<i>Totals</i>							799	114941		

Geographic Spread of Influenza Reported by State and Territorial Health Departments
2016-2017 Influenza Season Week 48 (November 27-December 3, 2016)

<i>Region</i>	<i>State</i>	<i>Week 44</i>	<i>Week 45</i>	<i>Week 46</i>	<i>Week 47</i>	<i>Week 48</i>
1	Connecticut	SPORADIC	SPORADIC	LOCAL	LOCAL	LOCAL
	Maine	LOCAL	SPORADIC	LOCAL	LOCAL	LOCAL
	Massachusetts	LOCAL	LOCAL	LOCAL	LOCAL	LOCAL
	New Hampshire	REGIONAL	REGIONAL	LOCAL	LOCAL	LOCAL
	Rhode Island	NONE	NONE	NONE	NONE	NONE
	Vermont	NONE	NONE	SPORADIC	SPORADIC	SPORADIC
2	New Jersey	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	New York	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Puerto Rico	REGIONAL	REGIONAL	REGIONAL	REGIONAL	WIDESPR
	Virgin Islands	SPORADIC	REGIONAL	REGIONAL	REGIONAL	SPORADIC
3	Delaware	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	District of Columbia	SPORADIC	SPORADIC	SPORADIC	SPORADIC	NO. REPT.
	Maryland	SPORADIC	LOCAL	SPORADIC	SPORADIC	LOCAL
	Pennsylvania	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	Virginia	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	West Virginia	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
4	Alabama	SPORADIC	SPORADIC	LOCAL	LOCAL	REGIONAL
	Florida	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Georgia	SPORADIC	SPORADIC	SPORADIC	LOCAL	SPORADIC
	Kentucky	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	Mississippi	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	North Carolina	SPORADIC	SPORADIC	LOCAL	REGIONAL	REGIONAL
	South Carolina	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Tennessee	SPORADIC	NONE	NONE	SPORADIC	SPORADIC
5	Illinois	NONE	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Indiana	SPORADIC	SPORADIC	LOCAL	LOCAL	LOCAL
	Michigan	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Minnesota	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	Ohio	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	Wisconsin	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
6	Arkansas	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Louisiana	SPORADIC	SPORADIC	SPORADIC	LOCAL	LOCAL
	New Mexico	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Oklahoma	LOCAL	LOCAL	LOCAL	SPORADIC	LOCAL
	Texas	SPORADIC	SPORADIC	LOCAL	LOCAL	LOCAL

<i>Region</i>	<i>State</i>	<i>Week 44</i>	<i>Week 45</i>	<i>Week 46</i>	<i>Week 47</i>	<i>Week 48</i>
7	Iowa	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Kansas	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Missouri	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Nebraska	NONE	NONE	NONE	SPORADIC	SPORADIC
8	Colorado	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Montana	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	North Dakota	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	South Dakota	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Utah	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Wyoming	SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
9	Arizona	SPORADIC	SPORADIC	SPORADIC	SPORADIC	LOCAL
	California	LOCAL	SPORADIC	SPORADIC	SPORADIC	SPORADIC
	Guam	REGIONAL	WIDESPR	REGIONAL	REGIONAL	REGIONAL
	Hawaii	LOCAL	LOCAL	LOCAL	SPORADIC	SPORADIC
	Nevada	SPORADIC	SPORADIC	SPORADIC	LOCAL	LOCAL
	10	Alaska	SPORADIC	SPORADIC	SPORADIC	SPORADIC
Idaho		SPORADIC	SPORADIC	SPORADIC	SPORADIC	SPORADIC
Oregon		LOCAL	LOCAL	LOCAL	LOCAL	LOCAL
Washington		SPORADIC	SPORADIC	LOCAL	LOCAL	LOCAL